Sold Out
Book Categories |
Summary | 1 | |
Cross-Cutting Recommendations | 2 | |
Uses of Antiprogestins: The Reproductive Cycle | 3 | |
Other Potential Therapeutic Uses of Antiprogestins | 8 | |
Antiglucocorticoid Effects of Antiprogestins | 13 | |
1 | Introduction | 14 |
Background and Historical Perspectives | 14 | |
The IOM Report | 17 | |
Cross-Cutting Recommendations | 17 | |
2 | Uses of Antiprogestins: The Reproductive Cycle (Part I) | 19 |
Contraception | 20 | |
Post-Coital Contraception | 22 | |
Menses Induction | 23 | |
3 | Uses of Antiprogestins: The Reproductive Cycle (Part II) | 26 |
Pregnancy Termination During the First Trimester | 26 | |
Pregnancy Termination During the Second Trimester | 30 | |
Cervical Ripening | 32 | |
Labor Induction in Late Pregnancy | 33 | |
Summary | 34 | |
4 | Other Therapeutic Uses of Antiprogestins | 36 |
Endometriosis | 36 | |
Uterine Leiomyomas (Fibroids) | 39 | |
Breast Cancer | 41 | |
Meningiomas | 48 | |
5 | Antiglucocorticoid Effects of Antiprogestins | 52 |
Glucocorticoid Function | 52 | |
Therapeutic Use of Mifepristone (RU 486) as an Antiglucocorticoid | 53 | |
Adverse Antiglucocorticoid Effects of Antiprogestins | 55 | |
6 | Animals as Models for Studying Antiprogestins | 57 |
App. A: Agenda for the IOM Workshop "Antiprogestins: Assessing the Science" | 65 | |
App. B: Background Papers and Presentations (In Order of Presentation at IOM Workshop) | 69 | |
B1 | 1993: RU 486 - A Decade on Today and Tomorrow | 71 |
B2 | Overview and Background: Mechanism of Action of Antiprogestins | 120 |
B3 | The Use of Antiprogestins in the Reproductive Cycle | 139 |
B4 | Potential Contraceptive Effects of Antigestogens | 148 |
B5 | Use of Antiprogestins Before 63 Days of Amenorrhea | 164 |
B6 | Uses of Antiprogestins After 63 Days of Amenorrhea | 174 |
B7 | Comments on Session II | 183 |
B8 | Use of Antiprogestins in the Management of Endometriosis and Leiomyoma | 189 |
B9 | Antiprogestins and the Treatment of Breast Cancer | 210 |
B10 | Uses of RU 486 as an Antiglucocorticoid | 229 |
B11 | Primate Models for the Study of Antiprogestins in Reproductive Medicine | 243 |
B12 | Antiprogestogens: Perspectives from a Global Research Program | 253 |
App. C: Observers at the Workshop on Antiprogestins | 278 | |
Index | 281 |
Login|Complaints|Blog|Games|Digital Media|Souls|Obituary|Contact Us|FAQ
CAN'T FIND WHAT YOU'RE LOOKING FOR? CLICK HERE!!! X
You must be logged in to add to WishlistX
This item is in your Wish ListX
This item is in your CollectionClinical Applications of Mifepristone Assessing the Science and Recommending a Research Agenda
X
This Item is in Your InventoryClinical Applications of Mifepristone Assessing the Science and Recommending a Research Agenda
X
You must be logged in to review the productsX
X
X
Add Clinical Applications of Mifepristone Assessing the Science and Recommending a Research Agenda, Mifepristone (RU486), the first clinically available antiprogestin, has generated great interest since its discovery in the early 1980s. Today, it is recognized that mifepristone, along with other antiprogestins, has a potentially significant therapeutic , Clinical Applications of Mifepristone Assessing the Science and Recommending a Research Agenda to the inventory that you are selling on WonderClubX
X
Add Clinical Applications of Mifepristone Assessing the Science and Recommending a Research Agenda, Mifepristone (RU486), the first clinically available antiprogestin, has generated great interest since its discovery in the early 1980s. Today, it is recognized that mifepristone, along with other antiprogestins, has a potentially significant therapeutic , Clinical Applications of Mifepristone Assessing the Science and Recommending a Research Agenda to your collection on WonderClub |